Raphael Pharmaceutical Inc 10-Q for FY2022 Q3
Raphael Pharmaceutical Inc. (RAPH)
About this 10-Q
Raphael Pharmaceutical Inc filed this 10-Q on November 14, 2022, covering the quarter ended September 30, 2022 (FY2022 Q3).
Headline figures
Quarter ended September 30, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $1.44M
- compared with a net loss of $416K a year earlier
- Diluted EPS
- $0.10
- up 233.3% from $0.03 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended:
OR
For the transition period from to
Commission file number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification No.) |
(Address of principal executive offices)
(Zip Code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| N/A | N/A | N/A |
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding
12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
The number
of shares of the registrant’s common stock, $0.01 par value, outstanding as of November 14, 2022 :
TABLE OF CONTENTS
| Page | ||
| PART I | ||
| Item 1. | Financial Statements | F-1 |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 1 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 6 |
| Item 4. | Controls and Procedures | 6 |
| PART II | ||
| Item 1. | Legal Proceedings | 7 |
| Item 1A. | Risk Factors | 7 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 7 |
| Item 6. | Exhibits | 8 |
i
Item 1. Financial Statements
RAPHAEL PHARMACEUTICAL INC. AND ITS SUBSIDIARY
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
AS OF SEPTEMBER 30, 2022
UNAUDITED
U.S. DOLLARS IN THOUSANDS
INDEX
- - - - - - - - - - -
F-1
RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS
U.S dollars in thousands (except for share and per share data)
| As of September 30, | As of December 31, | |||||||
| 2022 | 2021 | |||||||
| (Unaudited) | (Audited) | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| Fixed assets, net | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Other account payables and accrued expenses | ||||||||
| Payable to related party | - | |||||||
| Total current liabilities | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, $0.01 par value: Authorized: 21,020,560 shares at June 30, 2022 and December 31, 2021 | ||||||||
| Issued and outstanding: | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity (deficit) | ( | ) | ||||||
| Total liabilities and stockholders’ equity (deficit) | $ | $ | ||||||
The accompanying notes are an integral part of the condensed consolidated interim financial statements.
F-2
RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
U.S dollars in thousands (except for share and per share data)
| Nine months ended September 30, | Three months ended September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Unaudited | Unaudited | |||||||||||||||
| Research and development expenses | $ | $ | $ | $ | ||||||||||||
| General and administrative expenses | ||||||||||||||||
| Operating loss | ||||||||||||||||
| Total financial expense (income), net | ( | ) | ||||||||||||||
| Net loss | ||||||||||||||||
The accompanying notes are an integral part of the condensed consolidated interim financial statements.
F-3
RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)
U.S dollars in thousands (except for share and per share data)
| Common stock | Additional paid-in | Accumulated | Total | |||||||||||||||||
| Number | Amount | capital | deficit | equity | ||||||||||||||||
| Balance as of January 1, 2022 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Issuance of common stock and warrants | ||||||||||||||||||||
| Issuance of common stock in exchange for services | ||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balance as of June 30, 2022 | $ | $ | ( | ) | $ | |||||||||||||||
| Issuance of common stock and warrants | ||||||||||||||||||||
| Issuance of common stock in exchange for services | - | |||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balance as of September 30, 2022 | $ | $ | ( | ) | $ | ( | ) | |||||||||||||
| Common stock | Additional paid-in | Accumulated | Total | |||||||||||||||||
| Number | Amount | capital | deficit | equity | ||||||||||||||||
| Balance as of January 1, 2021 (*) | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| Issuance of share capital | ||||||||||||||||||||
| Effect of reverse recapitalization transaction | ||||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||
| Balance as of June 30, 2021 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Issuance of share capital | - | |||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||
| Balance as of September 30, 2021 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| (*) |
| (**) |
The accompanying notes are an integral part of the condensed consolidated interim financial statements.
F-4
RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
U.S dollars in thousands
| Nine months Ended September 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Share-based payment in exchange for services | ||||||||
| Changes in: | ||||||||
| Other current assets | ||||||||
| Account payables | ||||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchase of fixed assets | ( | ) | ||||||
| Net cash provided by investing activities | ( | ) | ||||||
| Cash flows from financing activities | ||||||||
| Receipt of a loan | ||||||||
| Proceeds from issuance of common stock and warrants | ||||||||
| Cash acquired in the reverse recapitalization | ||||||||
| Net cash provided by financing activities | ||||||||
| Change in cash and cash equivalents | ( | ) | ( | ) | ||||
| Cash and cash equivalents at the beginning of the period | ||||||||
| Cash and cash equivalents at the end of the period | $ | $ | ||||||
| Supplement disclosure of non-cash activities: | ||||||||
| Current assets (excluding cash and cash equivalents) | - | ( | ) | |||||
| Current liabilities | - | |||||||
| Reverse recapitalization effect on equity | - | |||||||
| Cash acquired in connection with reverse recapitalization transaction | - | |||||||
The accompanying notes are an integral part of the condensed consolidated interim financial statements.
F-5
RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
U.S dollars in thousands (except for share and per share data)
| NOTE 1:- | GENERAL |
| a. | Raphael Pharmaceutical Inc (formerly Easy Energy, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on May 17, 2007. The Company is headquartered in Tel Aviv-Jaffa, Israel. From April 1, 2011 until December 31, 2019, the Company was not active.
On May 14, 2021, Raphael and the Company, completed the Share Exchange pursuant to which
The Share Exchange was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, is considered a non-operating public shell, and is therefore not a business as defined in ASC 805. As the shareholders of Raphael received the largest ownership interest in the Company, Raphael was determined to be the “accounting acquirer” in the Share Exchange. As a result, the historical financial statements of the Company were replaced with the financial statement of Raphael for all periods presented. | |
| b. | Going concern and management plans |
The accompanying financial statements
have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical
trials, and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent
of the Company’s future operating losses and the timing of becoming profitable are uncertain. As of September 30, 2022, the Company’s
accumulated deficit was $
F-6
RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
U.S dollars in thousands (except for share and per share data)
| NOTE 1:- | GENERAL (Cont.) |
Management’s plans include, but are not limited to, raising capital in the United States. There can be no assurance that it will be able to successfully raise additional financing, including in a public offering, or obtain additional financing on a timely basis or on terms acceptable to the Company, or at all.
Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists in the event that additional funding does not occur. In the event the Company is unable to have its loan converted as planned or its repayment date deferred, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. If such sufficient financing or payment deferral is not received timely, the Company would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.
| NOTE 2:- | SIGNIFICANT ACCOUNTING POLICIES |
These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2021. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2021, are applied consistently in these consolidated interim financial statements.
| NOTE 3:- | UNAUDITED INTERIM FINANCIAL STATEMENTS |
The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.
| NOTE 4:- | SHAREHOLDERS’ EQUITY |
| a. | On March 2, 2022, the Company raised $ |
| b. | On March 15, 2022, the Company issued |
F-7
RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
U.S dollars in thousands (except for share and per share data)
| NOTE 4:- | SHAREHOLDERS’ EQUITY (Cont.) |
| c. | On April 28, 2022, the Company signed an agreement to raise $ |
| d. | On April 28, 2022 the Company and a certain investor signed a finder fee agreement according to which the Company will issue to the investor | |
| e. | On May 2, 2022, the Company signed several agreements to raise $
In addition, it was agreed that the Company will issue | |
| f. | On June 27, 2022, the Company signed an agreement to raise $ | |
| g. | On June 30, 2022, the Company issued |
F-8
RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
U.S dollars in thousands (except for share and per share data)
| NOTE 4:- | SHAREHOLDERS’ EQUITY (Cont.) |
| h. | On July 5, 2022 the Company singed several agreements with it’s executive officers: |
| 1. | Service agreement with Chief Executive Officer– the
Company entered into an agreement with Sheffa Enterprises Inc, a company wholly owned by the Company’s Chief Executive Officer (“CEO”).
According to the terms of the agreement, the CEO will provide services to the Company until December 31, 2024 (“termination date”).
The fees for his services will be $ |
| 2. | Service agreement with Chief Financial Officer– The
services will consist of financial services, legal advice and serve as a director of the Company. Base compensation will be $ |
| 3. | Consulting agreement with the Chief Technology Officer - the
Company entered into an amendment agreement with its Chief Technology Officer (“CTO”). The fees for his services will be
$ |
| i. | On
July 27, 2022, the Company issued |
| j. | On
September 8, 2022, the Company issued |
| k. | On
September 8, 2022, the Company issued |
F-9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q.
On May 14, 2021, Raphael Pharmaceutical Ltd., an Israeli company, and Easy Energy, Inc., a Nevada corporation, completed a share exchange agreement, or the Share Exchange, pursuant to which the shareholders of Raphael Pharmaceutical Ltd. became the holders of 90% of the issued and outstanding share capital of Easy Energy, Inc., while Easy Energy, Inc.’s shareholders hold, following the share exchange, 10% of Easy Energy, Inc. On May 19, 2021, as agreed by the parties to the Share Exchange, Easy Energy, Inc. changed its name to Raphael Pharmaceutical Inc. Unless otherwise mentioned or unless the context requires otherwise, when used in this prospectus, the terms “Raphael,” “Company,” “we,” “us,” and “our” refer to Raphael Pharmaceutical Inc. and its subsidiary, Raphael Pharmaceutical Ltd., or Raphael Israel. References to Easy Energy are to Easy Energy, Inc. Unless otherwise mentioned or unless the context requires otherwise, the information provided in this Quarterly Report on Form 10-Q relates to Raphael Israel.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:
| ● | the regulatory pathways that we may elect to utilize in seeking U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, and other regulatory approvals, if any; | |
| ● | obtaining (and the cost thereof) FDA and EMA approval of, or other regulatory action in Europe or the United States and elsewhere with respect to our product candidates; | |
| ● | the commercial launch and future sales of our product candidates and our advancement of product candidates for other indications in our pipeline; | |
| ● | the potential cost of our rheumatoid arthritis product candidate, or RA and RA product candidate, respectively, for patients; | |
| ● | our expectations regarding the timing of commencing clinical trials; |
1
| ● | our expectations regarding the supply of the active pharmaceutical ingredient for our product candidates; | |
| ● | third-party payor reimbursement for our product candidates; | |
| ● | our estimates regarding anticipated expenses, capital requirements and our needs for additional financing; | |
| ● | completion and receiving favorable results of clinical trials for our product candidates; and | |
| ● | the filing by us, and the subsequent issuance of patents to us, by the U.S. Patent and Trademark Office and other governmental patent agencies. |
The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. For a discussion of these and other risks that relate to our business and investing in our common stock, you should carefully review the risks and uncertainties described in this Quarterly Report on Form 10-Q, and those described from time to time in our future reports filed with the Securities and Exchange Commission. The forward-looking statements contained in this Quarterly Report on Form 10-Q are expressly qualified in their entirety by this cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Overview
We are a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD, oil. Unless indicated otherwise, we plan on using oil derived from cannabidiol, or CBD, strains with low levels of Tetrahydrocannabinol, or THC. All references to the use of CBD in our product candidates refer to CBD strains with less than 0.3% of THC.
We are currently in the pre-clinical development stage for our lead product candidate, our rheumatoid arthritis, or RA, product candidate for the treatment of RA. In addition, we are aiming to develop a pharmaceutical drug product for the treatment of hyperinflammatory syndrome inflammation related to COVID-19, or our COVID-19 product candidate, which may be based on data or studies related to our RA product candidate. Our goal is to become a leader in development of CBD oil-based pharmaceutical drug products for the treatment of indications in which we believe there is a high unmet medical need in a range of disorders, including those related to inflammation in the body, including RA and COVID-19.
The Company was incorporated in the State of Nevada in May 2007 and was formerly known as Easy Energy, Inc. On May 14, 2021, Easy Energy and Raphael Israel completed the Share Exchange, as a result of which, Raphael Israel’s shareholders own 90% of our Company and Easy Energy’s shareholders hold the remaining 10%. Raphael Israel was incorporated in 2019 in the State of Israel and has focused to date on developing its lead product candidate for the treatment of RA. Easy Energy did not have any ongoing business or operations before the Share Exchange and following the Share Exchange we adopted Raphael Israel’s business plan.
Initially, we intend to obtain approvals for our product candidates from the FDA and Medical Cannabis Unit of the Ministry of Health of Israel. Upon obtaining FDA approvals, or in the event that we are not successful in obtaining such approvals, we intend to apply for EMA and other countries’ governmental regulatory agencies approvals for our product candidates. If we are successful in obtaining FDA approvals for our product candidates, we intend to enter into royalty agreements with good manufacturing practice, or GMP, approved medical manufactures and distributors, having them using our medical formulas strains for the purpose of growing, cultivating, manufacturing, and distributing Raphael Pharmaceutical medical indications in their designated territories.
2
Critical Accounting Policies
Our financial statements are prepared in accordance with US GAAP. There are no critical accounting estimates for the years ended December 31, 2021 and 2020. Also, please see Note 2 of Part I, Item 1 of this Quarterly Report on Form 10-Q for the summary of significant accounting policies.
Results of Operations
Three months ended September 30, 2022 compared to the three months ended September 30, 2021
Revenues. We had no revenues during the three months ended September 30, 2022 and September 30, 2021.
Research and Development Expenses. Our research and development expenses totaled $332,000 for the three months ended September 30, 2022, representing a increase of $171,000, or 106%, compared to $161,000 for the three months ended September 30, 2021. The increase was primarily attributable to expenses recorded as a result of issuance of shares of common stock to a service provider of the Company.
General and Administrative Expenses. Our general and administrative expenses totaled $1,094,000 for the three months ended September 30, 2022, representing an increase of $837,000, or 325%, compared to $257,000 for the three months ended September 30, 2021. The increase was primarily due to expenses recorded as a result of issuance of shares of common stock to an executive officer of the Company in connection with his engagement with the Company.
Operating Loss. Our operating loss totaled $1,426,000 for the three months ended September 30, 2022, representing an increase of $1,008,000, or 241%, compared to $418,000 for the three months ended September 30, 2021.
Financial Expense/(Income). We recognized financial expense of $17,000 for the three months ended September 30, 2022, representing an increase of $19,000, or 650%, compared to financial income of $2,000 for the three months ended September 30, 2021. The increase was primarily due to an increase in exchange rate differences.
Net Loss. As a result of the foregoing, our net loss totaled $1,443,000 for the three months ended September 30, 2022, representing an increase of $1,027,000, or 246%, compared to $416,000 for the three months ended September 30, 2021.
Nine months ended September 30, 2022 compared to the nine months ended September 30, 2021
Revenues. We had no revenues during the nine months ended September 30, 2022 and September 30, 2021.
Research and Development Expenses. Our research and development expenses totaled $502,000 for the nine months ended September 30, 2022, representing a decrease of $50,000, or 9%, compared to $552,000 for the nine months ended September 30, 2021. The decrease was primarily attributable to expenses recorded as a result of issuance of shares of common stock to a service provider of the Company which were offset by a decrease in pre-clinical trial expenses, mainly due to the conclusion of the pre-clinical study in mice for Company’s RA product candidate in 2021.
General and Administrative Expenses. Our general and administrative expenses totaled $1,711,000 for the nine months ended September 30, 2022, representing an increase of $1,208,000, or 240%, compared to $503,000 for the nine months ended September 30, 2021. The increase was primarily due to expenses recorded as a result of issuance of shares of common stock to an executive officer of the Company in connection with his engagement with the Company and due to retirement fees paid in stock to one of the Company’s directors.
3
Operating Loss. Our operating loss totaled $2,213,000 for the nine months ended September 30, 2022, representing an increase of $1,158,000, or 109%, compared to $1,055,000 for the nine months ended September 30, 2021. The increase was primarily due to increased general and administrative expenses for the nine months ended September 30, 2022 compared to the corresponding period in 2021.
Financial Expense. We recognized financial expense of $42,000 for the nine months ended September 30, 2022, representing an increase of $39,000, or 1,300%, compared to $3,000 for the nine months ended September 30, 2021. The increase was primarily due to an increase in exchange rate differences.
Net Loss. As a result of the foregoing, our net loss totaled $2,255,000 for the nine months ended September 30, 2022, representing an increase of $1,197,000, or 113%, compared to $1,058,000 for the nine months ended September 30, 2021.
Liquidity and Capital Resources
Since inception, we have funded our operations primarily through our founder’s capital and capital received from Easy Energy. As of September 30, 2022, we had $93,000 in cash and cash equivalents, and have invested most of our available cash funds in ongoing cash accounts.
Net cash used in operating activities was $482,000 for the nine months period ended September 30, 2022, compared with net cash used in operating activities of $715,000 for the corresponding period in 2021. The $233,000 decrease in the net cash used in operating activities during the nine months period ended September 30, 2022, compared to the same period in 2021, was primarily the result of a decrease in pre-clinical trial expenses.
Net cash used in investing activities was $2,000 for the nine months period ended September 30, 2022, compared with zero net cash used in investing activities for the corresponding period in 2021. The decrease in the net cash provided by investing activities during the nine months period ended September 30, 2022, compared to the same period in 2021, was primarily due to the purchase of laboratory equipment.
Net cash provided by financing activities for the nine months period ended September 30, 2022 was $424,000 compared to $657,000 for the same period in 2021. The decrease in net cash provided by financing activities during the nine months period ended September 30, 2022 compared to the corresponding period in 2021 was mainly due to decrease in receipt of loan funds.
Off Balance Sheet Arrangements
Rambam Research Agreement
Pursuant to a research agreement with Rambam Med-Tech Ltd, or Rambam MT, entered into by the parties in July 2019, or the Research Agreement, the Company agreed to fund a research project, to be performed by Rambam MT, with a research plan aimed at identifying the effects of different cannabis strains on the function of immune cells. On October 28, 2020, the Company and Rambam MT agreed to expand the research plan to study the anti-inflammatory activities of cannabis extracts in an RA mouse model. On February 15, 2021, the Company and Rambam MT agreed to further expand the research plan to study the effect of cannabis extracts on the immunopathology of the COVID-19 disease. The initial term of the Research Agreement was 48 months. On October 24, 2022, the Company and Rambam MT entered into a supplement to the Research Agreement, or the Supplement Agreement, pursuant to which the Company exercised an option to extend the Research Agreement by additional two years.
Pursuant to the Research Agreement, we agreed to pay Rambam MT $1.4 million in four equal payments, due on the first day of August on each successive year from 2019 through 2022. Pursuant to the Supplement Agreement, we agreed to pay Rambam MT $960,000 plus VAT in four biannual payments from May 2023 through December 2024. Furthermore, in accordance with the terms of the Research Agreement, we and Rambam MT will have joint ownership of any IP created as a result of research programs covered by such agreement. In connection with the Research Agreement, Rambam MT agreed not to work, study or develop any technologies with other entities that compete with our work with Rambam MT for our COVID-19 product candidate or RA product candidate for a term of three and seven years, respectively, from the end of the parties’ collaboration with respect to the COVID-19 product candidate and seven years from the end of the term of the Research Agreement with respect to the RA product candidate.
4
Subject to commercial sales of any product candidate using the IP created as a part of the research covered by such agreement, Raphael Israel is required to pay Rambam MT a royalty in an amount equal to 6% of all net sales, subject to certain deductions, such as taxes paid by any purchaser, transportation and shipping costs, and other customary deductions.
As of September 30, 2022, the Company has made three of the four equal payments due pursuant to the Research Agreement, for a total amount of $1,050,000.
Way of Life Cannabis Agreement
In October 2020, Raphael Israel entered into an engagement agreement with Way of Life Cannabis Ltd., or Wolc, pursuant to which, subject to its completing the Share Exchange with Easy Energy, Raphael Israel will be provided with up to 15 liters of CBD oil, from a strain of cannabis during a term of 18 months, to be provided in two to three deliveries of between one to seven milliliters of CBD oil. In accordance with Raphael Israel’s agreement with Wolc, Raphael Israel has agreed to issue to certain persons affiliated with Wolc 3% of Raphael’s issued and outstanding share capital as of the date of the Share Exchange, to be provided in three equal issuances; provided, however, that such persons may elect to receive a cash payment of $100,000 instead of any one issuance of Raphael’s shares. In addition to the issuance of shares, Raphael Israel has also agreed to pay Wolc a royalty fee equal to 15% of the net royalties generated from sales of Raphael Israel’s pharmaceutical drug products that are developed at Rambam hospital in Israel.
Except for the above, we have not engaged in any off-balance sheet arrangements, such as the use of unconsolidated subsidiaries, structured finance, special purpose entities or variable interest entities.
We do not believe that our off-balance sheet arrangements and commitments have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Current Outlook
We have financed our operations to date primarily through proceeds from our founder’s capital and capital received from Easy Energy. We have incurred losses and generated negative cash flows from operations since inception in 2019. To date we have not generated revenue, and we do not expect to generate significant revenues from the sale of our products in the near future.
We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial doubt about our ability to continue as a going concern. At this time, there is no guarantee that we will be able to obtain an adequate level of financial resources required for the short and long-term support of our operations or that we will be able to obtain additional financing as needed, or meet the conditions of such financing, or that the costs of such financing may not be prohibitive. These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date of the financial statements included elsewhere in this prospectus.
As of September 30, 2022, our cash and cash equivalents were $93,000. We believe that our existing cash and cash equivalents will not be sufficient to fund our projected cash requirements through September 2023. Therefore, we will require significant additional financing in the near future to fund our operations. We currently anticipate that we will require approximately $1 million for research and development activities over the course of the next 12 months. We also anticipate that we will require approximately $2 million for capital expenditures over such 12-month period, which consists primarily of expenditures for clinical trials and general Company operating costs.
In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including:
| ● | our research and development efforts, including our ability to finish research and development projects or product development within the allotted or expected timeline; |
5
| ● | the cost, timing and outcomes of seeking to commercialize our products in a timely manner; | |
| ● | our ability to generate cash flows; | |
| ● | economic weakness, including inflation, or political instability in particular foreign economies and markets; | |
| ● | government regulation in our industry, and more specifically, the costs and timing of obtaining regulatory approval or permits to launch our technology in various geographical markets; and | |
| ● | the costs of, and timing for, strengthening our manufacturing agreements for production of our wave energy systems. |
In addition to the foregoing, based on our current assessment, we do not expect any material impact on our long-term liquidity due to the COVID-19 pandemic. However, we will continue to assess the effect of the pandemic to our operations. The extent to which the COVID-19 pandemic will impact our business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, any restrictions on the ability of hospitals and trial sites to conduct trials that are not designed to address the COVID-19 pandemic and the perceived effectiveness of actions taken in Israel, the United States and Europe and other countries to contain and treat the disease. While the potential economic impact brought by COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital in the future. In addition, a recession or long-term market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.
Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through our existing cash, cash equivalents and short-term deposits, loans, or debt or equity financings. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to, one or more applications of our products. This may raise substantial doubts about our ability to continue as a going concern.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not applicable.
Item 4. Controls and Procedures
Management’s Conclusions Regarding Effectiveness of Disclosure Controls and Procedures
As of September 30, 2022, we conducted an evaluation, under the supervision and participation of management including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Securities Exchange Act of 1934, as amended). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.
Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective at the reasonable assurance level as of September 30, 2022.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2022, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
6
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
There have been no material changes to our legal proceedings as described in “Item 3. Legal Proceedings” in our Annual Report on Form 10-K filed with the SEC on March 30, 2022.
Item 1A. Risk Factors
There have been no material changes to our risk factors from those disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 30, 2022.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Set forth below are the sales of all securities by the Company in the three months ended September 30, 2022, which were not registered under the Securities Act of 1933, as amended, or the Securities Act. The Company believes that each of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act and/or Regulation S under the Securities Act.
On July 5, 2022, the Company signed a service agreement with Sheffa Enterprises Inc. a company wholly owned by the Company’s Chief Executive Officer (“CEO”), pursuant to which the CEO was granted 1,000,000 warrants to purchase common stock at an exercise price of $1.12 per share. The warrants are exercisable until December 31, 2025.
On July 5, 2022, the Company signed a service agreement with the Company’s Chief Financial Officer (“CFO”), pursuant to which the CFO was granted 1,000,000 shares of common stock and 1,000,000 warrants to purchase common stock at an exercise price of $1.00 per share. The warrants are exercisable until December 31, 2025.
On July 5, 2022, the Company signed an amendment to the service agreement with the Company’s Chief Technology Officer (“CTO”), pursuant to which the CTO was granted with 990,000 warrants to purchase common stock at an exercise price of $0.01 per share. The warrants are exercisable until July 5, 2024.
On July 5, 2022, the Company signed an amendment to the service agreement with one of the Company’s directors, pursuant to which the director was granted with 202,000 warrants to purchase common stock at an exercise price of $1.12 per share. The warrants are exercisable until July 4, 2024.
On July 27, 2022, the Company issued 100,500 shares of common stock to Wolc in connection with the services agreement dated October 2020 by and among Wolc and the Company.
On September 8, 2022, the Company issued 56,000 shares of common stock to certain investors of the Company pursuant to a share purchase agreement for total consideration of $63,000. The funds for the shares were received during September 2022.
On September 8, 2022, the Company issued 102,000 shares of common stock to a service provider of the Company for his services.
7
Item 6. Exhibits
EXHIBIT INDEX
| Exhibit No. | Description | |
| 10.1* | Supplement to Sponsored Research Agreement with Rambam Med-Tech Ltd. | |
| 31.1* | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a). | |
| 31.2* | Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a). | |
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350. | |
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350. | |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104* | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
| * | Filed herewith. |
8
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| RAPHAEL PHARMACEUTICAL INC. | ||
| Date: November 14, 2022 | By: | /s/ Shlomo Pilo |
| Name: | Shlomo Pilo | |
| Title: | Chief Executive Officer (Principal Executive Officer) | |
| Date: November 14, 2022 | By: | /s/ Guy Ofir |
| Name: | Guy Ofir | |
| Title: |
Chief Financial Officer (Principal Financial Officer) | |
9
Exhibit 10.1
APPENDIX TO THE AGREEMENT DATE JULY 07, 2019
Signed at October 23, 2022
| Between: | Rambam Med-Tech Ltd Reg. no. 514496587 |
| By Roee Atlas – CEO | |
| (So Called: “Med- Tech”) | |
| AND Between: | Raphael Pharmaceutical Ltd Reg. no. 516054400 |
| By Shlomo Pilo –CEO | |
| (So Called: “Raphael”) |
WHEREAS, the parties signed research agreement on July 7, 2019 (So called: “the Primary Agreement”);
WHEREAS, Med-Tech had signed on December 31, 2020 an appendix to the Primary Agreement in which its extent the primary agreement for an extra of four years in terms & conditions as will set up between the parties;
WHEREAS, the parties will set up, herein, the terms & conditions for the extension of two years out of the four in this appendix;
WHEREAS, the description plan & the objectives of the new research development will be set forth herein;
Now, THEREFORE, in consideration of the promises & mutual covenants set forth herein, the parties agrees as follows:
| A. | Description of the Research Development: |
Development of a novel patentable formulation based on combination of purified cannabinoid and Cannabinoid Receptor’s antagonist to treat rheumatoid diseases
| B. | Research plan: |
Scientific background
Rheumatoid diseases are characterized by progressive chronic inflammation of the musculoskeletal system afflicting primarily the joints but can lead to systemic comorbidities like pulmonary diseases or vasculitis. Chronic inflammation results in cartilage and bone damage, which in the course of deterioration can lead to disability of the affected patient (Smolen, Aletaha, & McInnes, 2016).
Rheumatoid diseases have a great individual and societal burden. Pain and musculoskeletal deficits lead to a progressive decline in physical activity and quality of life and carry the risk of cumulative comorbidity. Medical costs for treatment as well as the reduction in work capacity and the decreased societal participation of patients with RA have a major socioeconomic effect on society (Cross et al., 2014).
Therapy of rheumatoid diseases is challenging not only because of the progressive nature of the disease but also because of the side effects of the current treatments available (Nawaz, Ali, Rehman, & Aslam, 2020). Moreover, available treatment options cannot reverse rheumatoid diseases. Thus, therapy efforts are followed in two directions: i) preventive medicine (starting treatment before clinical manifestation) and ii) development of new drugs that treat rheumatoid diseases. Three classes of drugs are available today; i) disease-modifying anti-rheumatic drugs (DMARDs), which target TNF, the IL-6 receptor and stimulate the depletion of T and B cells diminishing the progression of the structural damage (Singh et al., 2016; Smolen et al., 2014), ii) non-steroidal anti-inflammatory drugs (NSAIDS), which improve the physical function by reducing pain and stiffness but do not modify the disease (Nawaz et al., 2020) and iii) glucocorticosteroids, which have a rapid symptomatic and disease-modifying effect (Kirwan, 1995).
Prolonged use of glucocorticoids and DMARDs has serious long-term adverse effect (Szostak, Machaj, Rosik, & Pawlik, 2020; Yasir, Goyal, Bansal, & Sonthalia, 2020). Moreover, biological DMARDs have an increased risk of serious infections by tuberculosis and herpes zoster virus as well as the risk to develop melanoma (Ramiro et al., 2014). This exemplifies the need for novel treatment approaches and safe therapeutics. One of them might be the usage of medical cannabis taking advantage of its pain-reducing and immune-modulating features.
Cannabis and cannabinoids
Cannabis is the most widely used illicit drug in the world. It is not a single substance but refers to a compilation of > 550 different chemical constituents accumulated in the cannabis plant, among them ≈ 150 psychoactive and non-psychoactive cannabinoids and > 400 non-cannabinoids. The cannabis plant belongs to the family Cannabaceae. Two different forms are distinguished; cannabis with high levels of the psychoactive tetrahydrocannabinoids (THC) is referred to as marijuana and cannabis with high levels of non-psychoactive cannabinoids and low levels of THC is referred to as hemp (Baron, 2015). Two main THC compounds are pharmacologically active, 8-THC and 9-THC. The main non-psychoactive but pharmacologically active cannabinoids are cannabinol (CBN), cannabidiol (CBD) or cannabigerol (CBG) (Figure 1) as well as non-cannabinoids like flavonoids, terpenes and fatty acids (Andre, Hausman, & Guerriero, 2016; Gould, 2015).
2
Figure 1: Cannabinoids in the cannabis plant
List and number of phytocannabinoids found in the cannabis plant.
Cannabis and cannabinoids occur in several forms; as they occur in the cannabis plant or as isolates and synthetic or semi-synthetic produced substances.
Natural cannabinoids
Medical cannabis is available as the whole plant in the form of dried flowers or as extracts thereof. Drying and heating allows gradual decarboxylation of the cannabinoid acid precursors into the proper neutral forms, i.e. cannabidiol acid (CBDA) converts to cannabidiol (CBD) or tetrahydrocannabinol acid (THCA) converts to tetrahydrocannabinol (THC) (de Meijer et al., 2003). Physiologic effects of non-cannabinoids that are also found in the leaves and flowers are not yet entirely known (Sarzi-Puttini, Batticciotto, et al., 2019).
Synthetic and semi-synthetic cannabinoids
Many off the shelf products are available, of which three cannabis products received approval for medicinal use. These are nabiximol which consists of natural THC and CBD extracts, dronabinol which is plant-derived but chemically modified after extraction and nabilone is synthetically produced (Häuser, Petzke, & Fitzcharles, 2018; Mücke, Phillips, Radbruch, Petzke, & Häuser, 2018).
Nabiximols, better known under the tradename Sativex®, is a botanical mouth spray that received approval in the UK in 2010 for the alleviation of MS-symptoms like spasticity, pain and overactive bladder. Its main ingredients are THC and CBD at similar dosage (Häuser et al., 2018; Mücke et al., 2018; Sarzi-Puttini, Batticciotto, et al., 2019).
3
Dronabinol (Marinol) contains mainly THC and is a partial agonist of the cannabinoid receptors CB1 in the nervous system and CB2 in the periphery that activates appetite, mood, cognition, memory and perception. Dronabinol received FDA-approval for the United States in 1985 for treatment of anorexia in AIDS patients and for the prevention of chemotherapy-induced nausea and vomiting (CINV). Adverse effects include drowsiness, fatigue, dizziness, conjunctivitis, paranoia and abnormal thinking and euphoria as well as gastrointestinal problems like nausea, vomiting, abdominal pain and diarrhea (Häuser et al., 2018; Mücke et al., 2018). Lack of randomized controlled trials (RCTs) makes a recommendation for usage of dronabinol as a third-line treatment for CINV difficult (Sarzi-Puttini, Batticciotto, et al., 2019). Dronabinol in the form of an oral tablet is known under the trade name namisol. It has high bioavailability and a long shelf life and is indicated for Multiple Sclerosis (MS), chronic pain and behavioral disturbances in dement patients (Häuser et al., 2018; Sarzi-Puttini, Batticciotto, et al., 2019).
Nabilone with the main ingredient THC is approved and sold under the brand name Cesamet in Canada, Mexico, the UK and the USA as an anti-emetic and adjunctive analgesic for neuropathic pain, CINV and treatment for anorexia in AIDS patients. Its main usage today is as adjunct medicine for chronic pain management. However, ambiguous results from case studies and clinical trials on benefits of nabilone for fibromyalgia and MS were published so that recommendations for usage cannot be given (Häuser et al., 2018; Reekie, Scott, & Kassiou, 2017; Sarzi-Puttini, Batticciotto, et al., 2019).
Signaling pathways and the importance of cannabinoid receptors for signal transduction
Cannabinoids mediate their biological and therapeutic effects through cannabinoid receptors (Mackie, 2008; Paland et al., 2021; T. H. Smith, Sim-Selley, & Selley, 2010). At least two members of the G-protein coupled receptor family (GPCRs), cannabinoid receptors 1 (CB1R) and 2 (CB2R), were identified. G-proteins act as adaptors that link GPCRs to other signaling and regulatory proteins to operate or modulate intracellular signaling pathways. Other G-protein coupled receptors such as GPR55 and GPR18 and transient receptor potential channels such as TRPV2, TRPA1, or TRPM8 are involved in cannabinoid signaling (Rosenbaum, Rasmussen, & Kobilka, 2009).
CB1R is highly expressed on neural cells in the central nervous system (CNS), and is found in particularly high levels in the neocortex, hippocampus, basal ganglia, cerebellum and brainstem (Marsicano & Kuner, 2008). Low expression levels are observed in the peripheral nervous system. The CB1R binds the main active ingredient of marijuana, Δ9-THC, and mediates most of the CNS effects of THC (Zimmer, Zimmer, Hohmann, Herkenham, & Bonner, 1999).
CB2R is present at high levels in cells of the immune system and commonly associated with the regulation of immune function. Furthermore, a functionally relevant expression of CB2R was also found in the brain (Salort, Álvaro-Bartolomé, & García-Sevilla, 2017). In the CNS, CB2R expression is associated with inflammation and it is primarily localized to microglia, resident macrophages of the CNS (Palazuelos et al., 2009).
4
The fact that both CB1 and CB2 receptors have been found on immune cells suggests that cannabinoids play an important role in the regulation of the immune system. It has been shown to exert anti-inflammatory activities in various in vivo and in vitro experimental models. Several studies showed that cannabinoids downregulate cytokine and chemokine production and, in some models, upregulate T-regulatory cells as a mechanism to suppress inflammatory responses (Berdyshev, 2000; Paland et al., 2021).
Cannabinoids can inhibit cell proliferation through various mechanisms. They block cell cycle progression at the G1/S phase via CB1R and at the G2/M phase via CB2R activation by inhibiting Akt and ERK signaling. CB1R activation inhibits the FAK/SRC/RhoA pathway leading to inhibition of cell migration. Cell migration blockade is also achieved by CB2R activation through the inhibition of COX-2 and ERK signaling, which is important to suppress inflammatory response (Kisková, Mungenast, Suváková, Jäger, & Thalhammer, 2019).
| C. | Research Objectives |
The overall objective of this study is to identify a novel cannabinoid based patentable formulation to treat Rheumatoid diseases. Specifically, to investigate combination of purified cannabinoids with cannabis receptors antagonists to downregulate inflammation related to Rheumatoid diseases. We propose to base our study on data derived from Dr. Igal Louria-Hayon studies (Helsinki # 0442-20-RMB) on the evaluation of the immune regulation properties of cannabinoids on the immune system and the data derived from the cannabinoids receptors study (Helsinki # 0331-20-RMB). We will analyze the activation of cannabinoid receptors on mouse models and will study the role of cannabinoid receptors antagonists as a potential to develop a novel patentable formulation to treat Rheumatoid Arthritis.
Specific aims:
| 1. | Identify the potential of purified specific cannabinoid on Rheumatoid Arthritis in a mouse model |
| 2. | Identify Cannabinoid Receptors antagonist with a potential to downregulate immune cells activities, in human derived cells and mouse model. |
| 3. | Formulate a combination of purified cannabinoid and Cannabinoid receptors antagonist which will demonstrate synergistic effect to downregulate inflammation related to Rheumatoid Arthritis. |
We suggest that our strategy to combine purified cannabinoid together with cannabinoid receptor’s antagonists, will allow us to develop a novel formulation for Rheumatoid Arthritis treatment.
5
| D. | Cost of the New research Development: |
Raphael will sponsored the new research development as follows:
2 years Budget (cost including overhead):
Pre-Clinical lab research cost $700,000 USD + V.A.T.
Mouse model for systemic inflammation: 120,000 USD + VAT.
Mouse model for Rheumatoid Arthritis: 140,000 USD + VAT.
Total cost: 800,000 + 160,000 (overhead) + VAT.
| ● | The principal investigator is authorized to decide on changes in the budget of each category and the duration of the research in related to the needs of the study. |
Payment Schedule:
Raphael Pharmaceutical will pay to Rambam MedTech
1st payment: 100,000$ + 20,000$ overhead on May 2023 (Mouse Model).
2nd payment: 291,667$ + 58,333$ overhead on December 2023 (Research year I).
3rd payment: 116,667$ + 23,333$ overhead on May 2024 (Mouse Model).
3rd payment: 291,667$+ 58,333$ overhead $ December 2024 (Research Year II).
All payments should be added VAT
Payment will be in NIS according to the Bank of Israel exchange rate on the day of payment.
6
IN WITNESS WHEREOF, each party has caused this Appendix to be executed by its duly authorized representative as of the effective date:
| Rambam Med-Tech Ltd | Raphael Pharmaceutical Ltd | |||
| By: | /s/ Roee Atlas | By: | /s/ Shlomo Pilo | |
| Name: | Roee Atlas | Name: | Shlomo Pilo | |
| Title: | CEO | Title: | CEO | |
| Date: | 23.10.22 | Date: | 24.10.22 | |
| Principal Investigator | ||
| By: | /s/ Igal Louria- Hayon | |
| Name: | Igal Louria- Hayon | |
| Title: | Scientific Director Medical Cannabis Research and Innovation Center Rambam health care Campus. | |
| Date: | 23.10.2022 | |
7
Exhibit 31.1
CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a)
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
I, Shlomo Pilo, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Raphael Pharmaceutical Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant ’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Date: November 14, 2022 | By: | /s/ Shlomo Pilo |
| Shlomo Pilo | ||
| Chief Executive Officer |
Exhibit 31.2
CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a)
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
I, Guy Ofir, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Raphael Pharmaceutical Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant ’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Date: November 14, 2022 | By: | /s/ Guy Ofir |
| Guy Ofir | ||
| Chief Financial Officer |
Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the quarterly report of Raphael Pharmaceutical Inc., or the Company, on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Shlomo Pilo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
| 1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Dated: November 14, 2022 | /s/ Shlomo Pilo |
| Shlomo Pilo | |
| Chief Executive Officer |
Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the quarterly report of Raphael Pharmaceutical Inc., or the Company, on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Guy Ofir, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
| 1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Dated: November 14, 2022 | /s/ Guy Ofir |
| Guy Ofir | |
| Chief Financial Officer |